Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 10/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.36 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
| ▸ | ACACA | Q13085 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5249986 | 0.90 | CCR3 (0.37) | CCR3HRH3L3MBTL3L3MBTL1LRRK2 | |
| SCHEMBL4722465 | 0.88 | CCR3 (0.41) | CCR3HRH3L3MBTL3L3MBTL1LRRK2 | |
| SCHEMBL3314680 | 0.88 | CCR3 (0.41) | CCR3HRH3L3MBTL3L3MBTL1LRRK2 | |
| SCHEMBL5248989 | 0.86 | RAMP1 (0.42) | CCR3HRH3LRRK2ACACBACACA | |
| SCHEMBL4717935 | 0.86 | CCR5 (0.36) | CCR3HRH3L3MBTL3L3MBTL1CCR5 | |
| SCHEMBL3311181 | 0.86 | CCR5 (0.36) | CCR3HRH3L3MBTL3L3MBTL1CCR5 | |
| SCHEMBL3284870 | 0.84 | CCR5 (0.41) | CCR3L3MBTL3L3MBTL1CCR5ACACB | |
| SCHEMBL3285188 | 0.84 | CCR5 (0.41) | CCR3L3MBTL3L3MBTL1CCR5ACACB | |
| SCHEMBL4717841 | 0.81 | CCR5 (0.39) | CCR3HRH3L3MBTL3L3MBTL1CCR5 | |
| SCHEMBL4718312 | 0.81 | CCR5 (0.39) | CCR3HRH3L3MBTL3L3MBTL1CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249592-A1 | Use of selected CGRP antagonists in treatment and prevention of hot flushes in prostate cancer patients | RUDOLF KLAUS | 2007-10-25 | — | — | US | disclosed |
| EP-1833484-A1 | USE OF CGRP ANTAGONISTS IN TREATMENT AND PREVENTION OF HOT FLUSHES IN PROSTATE CANCER PATIENTS | Boehringer Ingelheim International GmbH (DE) | 2007-09-19 | — | — | EP | disclosed |
| US-20060154921-A1 | Use of CGRP antagonists in treatment and prevention of hot flushes in prostate cancer patients | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-07-13 | — | — | US | disclosed |
| WO-2006069754-A1 | USE OF CGRP ANTAGONISTS IN TREATMENT AND PREVENTION OF HOT FLUSHES IN PROSTATE CANCER PATIENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154921-A1 | Use of CGRP antagonists in treatment and prevention of hot flushes in prostate cancer patients | CALCA, CALCB, CALCR | CCR3 689/4885HRH3 78/4885L3MBTL3 4703/4885 |
| US-20070249592-A1 | Use of selected CGRP antagonists in treatment and prevention of hot flushes in prostate cancer patients | CALCA, CALCB, BDKRB2 | CCR3 726/4885HRH3 84/4885L3MBTL3 4647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.